BridgeBio Pharma (BBIO) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 22.6% versus a gain of 9.1%. Over five years, MDGL leads with a +453.5% price change compared with +38.6% for BBIO. BridgeBio Pharma is the larger company by market cap ($12.71 billion vs $11.02 billion), about 1.2 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +126.3%).
On valuation, Madrigal Pharmaceuticals trades at a lower forward P/E (49.5x vs 2367.7x for BridgeBio Pharma). Madrigal Pharmaceuticals converts more of its revenue into profit, with a net margin of -30.1% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | MDGL |
|---|---|---|
| Share price | $65.04 | $476.91 |
| Market cap | $12.71B | $11.02B |
| 1-day change | -2.20% | -2.22% |
| YTD return | -13.06% | -18.10% |
| 1-year return | +22.65% | +9.15% |
| 5-year return | +38.60% | +453.45% |
| Forward P/E | — | 49.55 |
| EPS (TTM) | $-3.56 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $958.40M |
| Revenue growth (YoY) | +126.26% | +432.05% |
| Net income (latest FY) | $-732.94M | $-288.28M |
| Gross margin | 95.82% | — |
| Operating margin | -104.25% | -31.31% |
| Net margin | -145.98% | -30.08% |
| 52-week high | $93.42 | $615.00 |
| 52-week low | $52.75 | $393.61 |
| Distance from 52-week high | -30.38% | -22.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.67% | +43.03% |
| Average volume | 2.48M | 289.24K |
| Shares outstanding | 195.49M | 23.10M |
| Employees | 999 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed MDGL by 13.5 percentage points over the past year.
- Madrigal Pharmaceuticals is more profitable, keeping -30.1 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +126.26%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
BBIO vs MDGL FAQ
Which is bigger, BridgeBio Pharma or Madrigal Pharmaceuticals?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $12.71B compared with $11.02B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, BBIO or MDGL?
BBIO returned +22.65% over the past 12 months, compared with +9.15% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.